|
The Autism Society, Immunize.org and Vaccinate Your Family have collaborated to develop a new infographic, The Facts About Autism and Vaccines. This resource dispels common myths and misconceptions about a link between vaccines and autism by highlighting the scientific evidence. It’s a valuable tool to add to your resources as you work to reassure and support families with accurate vaccine information.
Related resources:
Vaccine Education Initiative | Autism Society
The Truth About Autism and Vaccines VYF-ASF Guide 2025
Autism and Vaccines - Autism Science Foundation
Vaccine and Autism: What You Should Know Q&A | Children's Hospital of Philadelphia
Autism: Resources & Information | Immunize.org
Two new products have been added to the Vaccines for Children (VFC) Program and will be available to order beginning Oct. 1, 2025:
-
Enflonsia (Clesrovimab - RSV Monoclonal Antibody): Recommended for infants under eight months who are entering their first respiratory syncytial virus (RSV) season and whose mothers did not receive RSV vaccination during pregnancy based on current recommended dosing and schedules. A single intramuscular dose provides season-long protection. Enflonsia is an option in addition to Beyfortus (nirsevimab) for RSV protection. All infants should be protected against RSV through either maternal RSV vaccination or receipt of a long-acting RSV monoclonal antibody (clesrovimab or nirsevimab).
-
PENMENVY (MenABCWY Vaccine): A new 5-in-1 meningococcal vaccine protecting against serogroups A, B, C, W, and Y. Approved for ages 10–25 and given in a 2-dose series, 6 months apart, according to current recommended dosing and schedules. PENMENVY combines coverage previously requiring two separate vaccines, helping simplify adolescent immunization. Penmenvy is an option in addition to Penbraya when both MenACWY and MenB would be given at the same visit.
Providers can now order both products in KSWebIZ. Please review storage, handling, and administration guidance to ensure readiness for use.
If you have any questions or concerns, please contact your Regional Immunization Nurse or the Immunization Nurse On-Call at 877-296-0464.
Related links:
Available to Order | ENFLONSIA™ (clesrovimab-cfor) | Official HCP Web Site
Use of Clesrovimab for Prevention of Severe Respiratory Syncytial Virus–Associated Lower Respiratory Tract Infections in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2025
U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season - Merck.com
ACIP Recommendation - PENMENVY (Meningococcal Groups A, B, C, W, and Y Vaccine)
The Immunize Kansas Coalition (IKC) is excited to share two new resources to support flu vaccine uptake this season:
- Designed for healthcare professionals and teams, IKC’s Preventing Flu Education Module details the burden of influenza disease, explores Kansas' immunization rates, and dives into recommended methods for increasing immunization rates in the office setting. Viewers will also practice giving patients succinct and accurate answers to questions about the flu vaccine and flu. This is a half hour Continuing Education (CE) activity. CE is available at no cost to physicians, pharmacists, physician assistants, nurses, and nurse practitioners.
- IKC’s #FluVaxFacts campaign provides easy-to-understand answers to common flu questions. Topics include the best time to get vaccinated, who is at the highest risk from the flu, where to access flu vaccines, and more. Share these graphics on social media with the provided captions and join us in the effort to #BeatFlu.
These resources and other tools can be found on IKC’s KansasFightsFlu webpage.
Vaccines for Children (VFC) providers play an important role in making sure publicly funded vaccines are available for the children they serve. Planning ahead is the best way to keep things running smoothly. Borrowing should be reserved for rare, unexpected situations, not as part of everyday practice.
Relying on borrowing too often can create extra work for staff, lead to mix-ups, and cause compliance concerns.
VFC funded vaccine should never serve as a regular backup supply for privately purchased vaccine. Borrowing is allowed only in rare, unplanned circumstances, such as:
-
Seasonal influenza exception: If VFC influenza vaccine is not yet available, providers may temporarily use private influenza vaccine for publicly insured children and replace it when VFC vaccine arrives. This one-way exception applies to influenza vaccine only. Seasonal flu vaccine must be repaid during the same flu season.
-
Shipment issues: When vaccine is delayed or spoiled.
-
Short-dated vaccine: To avoid wastage when a private vaccine dose is close to expiration and would otherwise be lost. This applies mainly to providers with very small privately insured populations.
-
Ordering error by new staff: If inexperienced staff incorrectly calculated ordering intervals before receiving proper training.
Even in these situations, borrowing must never prevent a publicly insured child from receiving the vaccine they need.
For providers who choose not to carry private vaccine, borrowing is not an option. VFC publicly funded vaccine must only be used for children who qualify for the VFC program.
Providers are encouraged to plan ahead for vaccine needs, particularly when preparing for scheduled mass immunization clinics. Having an adequate inventory in place before these events helps avoid unnecessary challenges, as borrowing is not intended for planned clinics.
If borrowing does become necessary, a Vaccine Borrowing Report must be completed for each instance. This applies whether VFC vaccine is temporarily used for privately insured children or private vaccine is used for publicly insured children. The report is considered complete once the borrowed dose has been replaced through actual administration. The Vaccine Borrowing Report is available on the KDHE Vaccines for Children Program webpage.
Completed reports can be submitted at the end of each month by fax to 785-559-4226 or by email to kdhe.vaccine@ks.gov. Providers should also keep a copy of each report on file for at least three years. When public vaccine is borrowed, documentation of the private vaccine purchase used for replacement should also be retained. These records may be reviewed during site visits or upon request.
In situations where borrowing occurs frequently, the Kansas Immunization Program (KIP) will connect with providers to provide support and ensure appropriate practices are in place.
By maintaining accurate ordering practices and careful vaccine management, clinics can help make sure the right vaccine is available for the right child, while keeping the process simple and stress-free for staff.
For questions regarding borrowing, contact your Regional Immunization Nurse or the Nurse On-Call at 877-296-0464.
The 2024-2025 academic year data, the most recent year surveyed, has been added to the KDHE Kindergarten Immunization Coverage Dashboard. This dashboard provides statewide, county level, and school district level data on up-to-date vaccination coverage for school entry vaccines for kindergarteners in Kansas. The dashboard also provides data on exemption rates for religious and medical exemptions.
Data for the dashboard come from the Kindergarten Vaccination Assessment Survey that is conducted annually. To learn more about the survey methodology, please see the Methodology and Technical Notes. Please see Kindergarten Vaccination Coverage Dashboard to view the full dashboard.
World Meningitis Day, on Oct. 5, brings attention to the global burden of meningitis and the importance of prevention through vaccination and early treatment. The day provides an opportunity for communities and organizations to come together to raise awareness and share reliable information about this serious disease. To support these efforts, a set of shareable graphics has been developed for use in newsletters, social media, and community outreach, helping to spread consistent messages and encourage informed action.
2025 PrEP WEEK - Topic: "Injectable PrEP" by Kenric Ware, PharmD, MBA, AAHIVP Sept. 25, 2025 at 11 a.m. CST.
Addressing Alcohol Use Disorder for Women of Childbearing Age with HIV Sept. 25, 2025 at 11 a.m. CST.
Nursing Transformation 2025 CNE Conference: From Insight to Impact Nurses Shaping the Future Sept. 29, 2025 at 7 a.m. CST.
Check out our full training list.
|
